The resale registration is a routine contractual step following the private placement. Monitor the pace of selling by the institutional holders listed in the filing, as their sales could create near-term overhang. The company's cash runway into 2028 reduces urgency for additional capital raises.
Drug in focus
LYEL drug pipeline →ronde-cel
▲ Bullish Named in this S-3- Impact
- Phase
- Phase 3
- Time to market
- Pivotal data from the PiNACLE trial is expected mid-2027, with a BLA submission planned for the second half of 2027. If approved, commercial launch would likely follow in 2028.
- Next catalyst
- None dated
What to watchThe next major catalyst is the ASH 2026 Annual Meeting (December 12-15, 2026), where updated data from the PiNACLE pivotal trial (3L+) and the Phase 1/2 second-line cohort will be presented in oral and poster sessions. Strong data could drive the stock toward analyst targets (mean $37.88), while disappointing durability or safety signals would pressure shares. The pivotal data readout expected in mid-2027 and BLA submission in H2 2027 are the longer-term binary events.
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lyell Immunopharma filed an S-3 registration statement to register 7,428,040 shares of common stock for resale by selling stockholders who acquired them in a private placement that closed on November 4, 2026 at $10.77 per share. The company will not receive any proceeds from the resale; the filing is a contractual obligation under the securities purchase agreement. The private placement raised $80M (stated in the prior earnings report) and extends the company's cash runway into 2028.
Key Financial Metrics
Key Facts
- S-3 registers 7,428,040 shares of common stock for resale by selling stockholders
- Shares were issued at $10.77 per share in a private placement that closed November 4, 2026
- Company will not receive any proceeds from the resale
- Maximum aggregate offering price calculated at $114,540,376.80 based on $15.42 reference price
- Selling stockholders include ARCH Venture Fund, T. Rowe Price, Caligan Partners, Euler Fund, Adage Capital, RTW Investments, Opaleye, Gates Frontier, Atlas Diversified, and Monashee Investment Management
- Private placement raised $80M extending cash runway into 2028 (per cross-filing context)
- Shares outstanding as of November 6, 2026: 32,015,715
Financial Impact
7,428,040 shares registered for resale, representing approximately 23.2% of shares outstanding at $10.77 per share (private placement price) or $114.5M at the $15.42 reference price used for SEC fee calculation
Risk Factors
- Potential overhang from selling stockholders reselling 7.4M shares into the market
- Company has filed 9 offering/registration filings in the last 24 months, indicating frequent capital market activity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-460585 |
| Document: d186264dexfilingfees.htm | 0001193125-26-460585 |
| Document: d186264dex51.htm | 0001193125-26-460585 |
| Document: d186264dex231.htm | 0001193125-26-460585 |
| Document: 0001193125-26-460585-index-headers.html | 0001193125-26-460585 |
| Document: 0001193125-26-460585-index.html | 0001193125-26-460585 |
| Document: 0001193125-26-460585.txt | 0001193125-26-460585 |
Track record
21 reports on LYEL
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +17.99% at T+60 after the Jun 8, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 13, 20263d ago S-3 Neutral 3/10 Viewing Entry $14.30 Now $14.65 +2.45% settles Nov 17
- Nov 12, 20264d ago Insider Cluster Bullish 6/10 Entry $14.30 to $14.65 Now $14.65 +2.45% ▲ +2.45% +4.36% vs SPY
- Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $16.86 to $15.64 Now $14.65 −13.11% ▼ −7.24% −6.88% vs SPY
- Nov 5, 202611d ago Insider Cluster Bullish 7/10 Entry $14.86 to $15.42 Now $14.65 −1.41% ▲ +3.77% +1.40% vs SPY
- Nov 4, 202612d ago 8-K Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.00 to $14.86 Now $14.65 −2.33% ▼ −0.93% −1.25% vs SPY
- Nov 4, 202612d ago 8-K Bearish 5/10 Entry $15.43 to $15.00 Now $14.65 +5.06% ▲ +2.79% −1.62% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $15.43 to $15.00 Now $14.65 −5.06% ▼ −2.79% +1.62% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 4/10 Entry $14.80 to $14.61 Now $14.65 −1.01% ▼ −1.28% −1.94% vs SPY
- Jul 22, 202616w ago EFFECT Neutral 4/10 Entry $12.84 to $12.78 Now $14.65 +14.10% ▼ −0.47% +0.77% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers